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ABSTRACT 
Staphylococcus aureus (S.aureus) is a pathogen causing infections. In recent years S.aureus 
formed resistance to most of known antibiotics on the market. It is today a global interest to find 
alternative treatment against multi drug resistant bacteria.  
 
The course of an infection is a multifactorial process. The first step after invasion is bacterial 
adhesion. Specific binding proteins are expressed on the cell surface of S. aureus with ability to 
bind different matrix proteins e.g. fibronectin, fibrinogen, collagen, laminin and vitronectin. 
Immunization with S.aureus adhesion proteins, recombinant developed in E.coli (Escherichia 
coli) gave rise to specific antibodies, targeting binding proteins on the cell wall of S.aureus and 
could block bacterial binding in vitro. Trials in vivo, performed in experimental endocarditis 
model in rats, further proved a significant protection against infection after immunization. 
  
To survive the environment after adherence and colonization, the invading microorganism need 
to express proteins interfering with the host immune system. Several extra cellular proteins 
expressed from S.aureus have a plurality of biological effects on the host.  Examples of these 
proteins, investigated in this survey, are Efb (extra cellular fibrinogen binding protein) and Eap 
(extra cellular adherence protein). Efb bind fibrinogen thus interfering with primary fibrin 
formation. Efb also bind and inactivate crucial factors in the complement system. These benefits 
of S.aureus are believed to cause delayed wound healing, prolonged bleeding and accessed scar 
formation found in S.aureus infected wounds.  
 
Eap has the ability to bind most of all known matrix proteins. It also serves several functions that 
interfere with the host immune system. This could be one explanation to the poorly functioning 
immunologic memory found after an S. aureus infection. 
 
The hypothesis in this thesis is mainly based on two theories: Disturbed adhesion primarily 
affect the virulence of an invading microorganism. Immunization with recombinantly produced 
adherence proteins stimulate opsonization and make hidden virulence factors visible to the 
immune system and thus facilitate the ability to clear out infections. The proteins expressed are 
representative for most common species of S. aureus, irrespective of antibiotic resistance. 
 
To mimic the clinical situation in experimental wound infection models it´s important to use 
small inoculate. It is also important to obtain a strong adaptive immune response with circulating 
memory cells that consequently would protect against recurrent infections. In the modern way of 
thinking it is also essential to attack several steps in the course of infection. An experimental 
wound infection model was thus performed, infected with a minimal infectious inoculate. Multi 
component immunization was performed with four recombinant proteins, targeted at different 
steps in the infectious process. The results indicated a significant reduction of bacterial load in 
the immunized group and a more rapid clearing out ratio compared to the control group after 
infection challenge with S.aureus. 
   
Conclusion: The present studies support the theory that it is conceivable to use immunizations 
with recombinant extra cellular and cell bound proteins as an alternative to prevent and further 
on treat infections caused by multi resistant microorganisms. 
Key words: Staphylococcus aureus, vaccination, surface bound adhesion proteins, extra cellular binding 
proteins, immunization. 
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1 INTRODUCTION 
1.1 History 
Infectious diseases and wound infection have followed humanity during the entire 
evolution. In 1847 Ignaz Semmelweis described the link between infection, 
microorganisms and the importance of hygiene [1]. Alexander Fleming (1881-1955) 
found in 1928 that moulds of Penicillium notatum in contaminated Lurial broth plates 
in vitro stunted growth of S aureus [2]. Fleming also demonstrated that injections with 
pure cultures of this fungus strain inhibited bacterial growth in vivo.  
 
 Dr. Howard Florey and Dr. Ernest Chain at Oxford University purified the active 
metabolite of penicillin and small quantities of the preparation could be produced in a 
powder form. Together with Dr. Andrew J Moyer, Peoria Lab, USA (1941) penicillin 
could be produced in a larger scale. Clinical trials ended 1943 and the preparation was 
tested for the first time in wounded allied soldiers after the D-day (invasion of 
Normandy) June 6 1944. Flemming Florey and Chain was awarded the Nobel Prize 
"for the discovery of penicillin and its curative effect in various infectious diseases" 
1945. Dr Andrew J Moyer patented the preparation technique of penicillin in May 
1948.  
 
1.2 Antibiotic resistance 
Mass production of penicillin was initiated in 1943. Four years later, 1947, the first 
report was published verifying the presence of antibiotic-resistant S aureus strains. 
Antibiotic resistance created a need to develop new types of antibiotics. Dr. Dorothy 
Crowfoot Hodgkin mapped the molecular structure of Penicillin and discovered the 
beta lactam ring (the active structure in beta lactam antibiotics). Different forms of 
antibiotics could later on be produced e.g. Tetracycline (1955), Nystatin (1957), active 
against fungal infections and Amoxicillin (1981) [2].  Dr Dorothy Crowfoot Hodgkin 
mainly conducted the research. In 1964 she was awarded the Nobel Prize in chemistry.  
Many of these drugs are used widely even today. Penicillin G is still active against 
infections caused by, e.g. Streptococci and Pneumococci. 
 
Common characteristic of most penicillin’s used today is the limited effect against S. 
aureus. This microorganism has developed resistance, e.g. beta-lactamase (irreversibly 
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opens the beta-lactam ring) and also resistance against most of the known antibiotics on 
the market. Antibiotic resistance could be inherited by different S.aureus species in but 
might also be developed, either by spontaneous mutations in chromosomal DNA or by 
absorption of plasmids (extra chromosomal DNA) from other closely related 
microorganisms. This feature is also shared with other pathogens e.g. Haemophilus 
influenzae, Enterococci and E. coli [3]. 
 
1.3 MRSA 
Antibiotic resistance became an increasingly growing problem in the world [4]. The 
first penicillinas stabile antibiotic, Methicillin, was introduced 1959. Two years later, in 
1961 the first Methicillin-resistant Staphylococcus aureus strain (MRSA) were reported 
from England [5]. Soon thereafter several case reports came from Europe, Japan, 
Australia, and United States. MRSA is today a global health problem in hospitals 
around the world and is still an increasing problem. It is believed that the gene mecA, 
encoding the penicillin binding protein 2A (PBP2A), is acquired from distant related 
species [6]. 
 MRSA is, surprisingly enough, a fairly common species in marine mammals e.g. 
Bottlenose dolphins [7, 8]. Many authors claim that the resistant strains were 
contaminants from the environment, but the most likely theory is that the marine 
mammals from time immemorial are colonized with MRSA. The marine mammals 
may simply have been used as a natural habitant for this specific microorganism [7, 8]. 
 The gene mecA is located in a mobile genetic element called the SCC mec 
(staphylococcal Cassette Chromosome mec). The mecA gene and the trans membrane 
β-lactam sensing signal transducer mecR1 are regulated by a repressor gene mec1. 
When exposed to beta-lactam antibiotics,  mecR1 is auto-catalytically cleaved and its 
metallo-protease domain cleaves in turn mec1, which allows the transcription of mecA 
(Fig. 1) [6, 9]. 
  Several different forms have been described, with variation in size and genetic 
structure [6, 9]. Most MRSA strains are resistant to all known antibiotics, apart from 
glycopeptides (e.g. Vancomycin). 
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A wide range of biological effects regarding interactions between Staphylococcus 
aureus extra cellular adherence protein (Eap) and host components is reported. 
Experimental mouse models have previously shown that injections with Eap, providing 
an inactivation of T cells, results in an inhibition of experimentally produced neuro 
inflammatory diseases such as MS (multiple sclerosis) [38], RA (rheumatoid arthritis) 
and Psoriasis [41, 42].  Eap also specifically interact with recombinant full-length OPN 
(osteopontin also known as bone sialoprotein I (BSP-1 or BNSP)) and the 40 kD N-
terminal MMP (matrix metalloproteinase) cleavage fragment and thereby inhibit the 
migration of cancer and bone metastasis in human breast cancer [43]. 
 
1.10 Immunity against S.aureus  
Adaptive immune response after an S.aureus colonization and infection is normally 
observed in healthy humans [44]. Circulating IgG antibodies can be demonstrated, 
targeting surface antigens, such as teichoic acid, clumping factors A and B, and bone 
sialoprotein-binding protein. Also antibodies are formed against extracellular proteins 
such as alpha-toxin, lipase, enterotoxin A, toxic shock syndrome toxin, scalded-skin 
syndrome toxin, Eap and Efb.  Variations between younger and elderly are found and 
some individuals are fairly "good responders" to several antigens, while others are 
"poor responders." [44]. Obviously these antibodies are not protective enough since all 
humans could get infected with S.aureus and yet be recurrently infected with the same 
pathogen [45]. 
 
As the bacteria adhere and multiply, expression of extra cellular proteins, interfering 
with host defence mechanisms is essential to the microorganism to survive and 
maintain infection. This might be the cause of long-term colonization, prolonged 
wound healing, severe scar formations and absence of efficient immunologic memory. 
 
1.11 The role of Eap blocking ICAM-1 / LFA 1 interaction  
Week non-specific selectin molecules P, E, and L selectin mediate the first stage of 
leukocyte-endothelial interaction. Inflammatory response will up regulate the 
expression of ICAM-1 thereby increasing the adhesive nature of leukocytes and 
endothelial cells.  The selectins initiate a “rolling behaviour” of the leucocytes over the 
endothelial layer.  ICAM-1 then interacts with leukocyte LFA-1 (Lymphocyte function-
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associated antigen 1) and stabilizes the leukocyte on to the endothelial layer. The next 
step is extravasation, the process were the leucocytes are crossing the endothelial layer, 
also called diapedesis. During diapedesis the PECAM-1 (Platelet / endothelial cell 
adhesion molecule 1) also named CD31 (cluster of differentiation 31) serves as a 
“gatekeeper” during the process. CD31 is expressed both on leukocytes and in the 
intercellular junctions of endothelial cells [46].  It is important to notice that the ICAM-
1/ LFA-1 interaction is not specific compared to the specific binding expressed on the 
bacterial surface (see above) and is only regulated by cytokines and factors concerning 
the inflammatory response [47]. 
 
 As the first step in antigen recognition Cytotoxic CD8 T cells use the previously 
mentioned non-specific interaction between ICAM-1 and LFA-1.  This interaction 
allows the T cell time to align the T cell receptor (TCR) with the MHC class I peptide 
complex (Major Histocompatibility Complex).  A successful TCR interaction will thus 
increase the adhesive force and initiate the effector function [48].   Conversely, an 
unsuccessful TCR interaction will not provide adequate adhesive forces and the T cell 
will simply leave the environment.  Analogous to the CD8-target cell / ICAM-1 
interaction, also other APC (antigen presenting cells) express ICAM-1 binding, but in 
this case to the MHC class II molecule.  APC also use ICAM-1 to hold CD4 T cells 
allowing time to initiate activation via interaction of the TCR and the MHC II peptide 
complex [49]. Eap binds ICAM-1 on activated endothelium and blocks the beta 1 and 2 
integrin on to leukocyte. This effect suppresses the cytokines, TNF - alpha (Tumour 
necrosis factor) and IL2 (Interleukin 2) signalling preventing the trans endothelial 
migration (see above).  Suppression of the cytokines TNF-alpha and IL-2 hence lead to 
an inactivation of both CD8 and CD4 lymphocytes. This could be one explanation to 
the weak immunologic memory after an S.aureus infection.  
 
1.12 Escaping the immune system 
Down regulation of ICAM-1 expression is related to different malignancies e.g. 
malignant melanoma, lymphoid and myeloid malignancies as well as allergic asthma, 
atherosclerosis, ischemia, neurological disorders, and organ transplant rejection [49]. 
As a well-known factor, human cancer has the ability to escape the immune system 
preferably via down regulation of cytotoxicity and up regulation of supressing factors 
involving IL-10 (interleukin 10) and TNF-beta (tumour necrosis factor beta). This will 
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lead to an overexpression of regulatory T4 helper cells or T-reg  (regulatory T- cells). In 
the environment of a solid cancer oxidative stress factors are expressed. Cytotoxic CD-
8 T-cells has proven to be significantly more sensitive to oxidative stress, compared to 
the regulatory T-cells [50] and consequently creates an immunosuppressing 
environment. In the surroundings of a chronic abscess caused by S.aureus, several 
proteins are expressed that contribute to increase the oxidative stress in the 
environment. It is therefore not inconceivable that the immunological response in a 
bacterial infected environment also is converted into a suppressive state.  
 
It can be hypothesized that neutralizing antibodies directed against adhesive and 
immuno modulating properties in the microorganism, like FnBP, Clf Eap and Efb, 
would result in a stronger immune response after immunization. Antibodies would 
make “hidden” virulence factor visible to the immune system, which would result in a 
milder infection and an infection easier to clear out via the innate and adaptive immune 
system.  It has also been shown that super-antigenic S.aureus stimulates Il 17 
(interleukin 17) production from old CD 4 cells but not from young CD 4 cells which 
proves that memory cells actually are present after an S.aureus infection [51], but they 
are obviously not protective against relapse [52-54]. Immunizations with recombinant 
proteins obtain a strong adaptive immune response and might also contribute to 
persisting memory cells that eventually would protect against recurrent infections. 
 
1.13 Endocarditis 
In Swedish material 29% of verified and 60% probable endocarditis are caused by 
viridans streptococci [55]. In almost all cases, the bacteria originate from the oral cavity 
[56] and in about half of these cases endocarditis was preceded by some kind of oral 
surgery [57]. The name viridans streptococci used in most articles is a synonym to Alfa 
streptococci. The following groups are part of the streptococcal family, associated with 
sub-acute endocarditis: Streptococcus sanguis type II, Streptococcus mutans, 
Streptococcus mitior and Streptococcus milleri.  
In addition to viridans streptococci, endocarditis is also caused by Staphylococcus 
aureus. This microorganism occurs mainly in the nose and on the skin [58, 59]. In the 
oral cavity, growth of S. aureus is present in approximately 20% of healthy "normal 
people" but in a higher rate in elderly, with other disorders and in young children [60, 
61]. Endocarditis caused by Staphylococcus aureus from wound injury in the skin is 
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fairly common on the right heart side without valvular deformities, e.g. in intra venous 
drug abusers [62, 63]. Bacteraemia occurs after surgery and from heavily infected 
wounds or infected deep burn injuries. Bacteria can be disseminated out into the blood 
stream, mainly through the lymphatic system. These microorganisms are usually 
eliminated by the reticuloendothelial system within a few minutes. In patients with 
valvular deformity or other organic heart diseases with sterile vegetations, circulating 
bacteria may adhere and cause endocarditis [64]. 
1.14 Recent vaccination trials during a decade 1996-2006 
 It is well known that an infection with S.aureus results in poor immunological 
protection and recurrent infections are common. Effective vaccines against 
staphylococcal infections do currently not exist. During the last century many attempts 
have been undertaken to finally prevent and cure infections caused by S. aureus. The 
number of invasive MRSA infections in the USA was estimated to be almost 100 000 
in 2005 [65] and the number is still increasing.  Approximately 112 million elective 
hospital operations were performed in 2005 [65]. Patients undergoing surgery could 
represent a major target for vaccination against S. aureus. Today there are at least seven 
active vaccination attempts at various stages of clinical development 
(GlaxoSmithKline/Nabi, Pfizer/Inhibitex, Sanofi Pasteur/Syntiron, Novartis, 
Novadigm, Integrated Biotherapeutics and Vaccine Research International) [66].  
Several reviews have described strategies to make the “optimal” vaccine, as well as 
highlighting the significant challenges of developing an effective S. aureus vaccine [67-
70]. The enthusiasm has been hampered by two late-stage failures to develop a safe and 
effective S. aureus vaccine. These previous vaccination attempts were mainly based on 
tree cornerstones. 
• Antigens in the two vaccines are expressed by a majority of S. aureus isolates.  
• The antigens produce a protective immune response in infection animal models 
[71, 72].  
• Antibodies against these antigens used in passive immunization animal studies, 
were shown to be protective [71, 72]. 
Nabi was the first company to take the challenge of testing a S. aureus vaccine in 
humans. The vaccine was based on two capsular polysaccharides type 5 and type 8 
(StaphVAX) [71]. In 2005, the project closed down due to failure of significance to 
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reduce S. aureus bloodstream infections in ESRD (end stage renal dialysis) patients. In 
June 2011 another company, Merck and Intercell were recommended by an 
independent data safety monitoring board to terminate phase II/III development of a 
subunit vaccine V710, containing a single antigen IsdB, a S. aureus cell surface 
localized iron regulated protein [73].  
Obviously the animal models of S. aureus infection used to evaluate early-stage 
vaccines were not predictive in clinical trials. It also appears, that capsular 
polysaccharides alone or one single protein antigen are not adequate enough to induce a 
protective immune response in humans. The use of haemodialysis patients with a 
suboptimal immune status was also frequently mentioned as a contributing factor to 
poor efficacy of StaphVAX.  Consequently a more appropriate patient population is 
required to evaluate efficacy of a vaccine. 
1.15 Future expectations of vaccines against S.aureus 
In several publications [66, 74-76] future expectations of efficient S. aureus vaccine 
development are described (Fig. 6).  
•  Multiple antigens (surface proteins, secreted proteins, toxoids and capsular 
polysaccharides) should be the dominant scientific approach in future vaccines.  
• The biological role of the immune response after immunization against S. 
aureus has to be evaluated in appropriate patient populations.  
• Immunization needs to develop targeting antibodies that 1: Directly inhibit 
bacterial viability and/or toxicity. 2: Antibodies that mediate opsonization. 3: 
Also a need to develop cell-mediated immunity that stimulate recruitment of 
phagocytes at the site of the infection. 
• A whole-cell S. aureus vaccine is also described to be an alternative to full 
safety and efficacy evaluation.  
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Fig.6. Future expectations of vaccines against S.aureus need to be targeting several 
different levels in the infectious process. 1. Specific antibodies that inhibit virulence 
factors. 2. Antibodies that stimulate opsonization 3. Stimulation of the adaptive immune 
system, to recruit neutrophils into the infected environment. 
 
A significant amount of capital is needed just to invest in clinical approvals. It is fairly 
unclear if the pharmaceutical companies are capable of investing in an efficacious S. 
aureus vaccine in the nearest future. Concerning the scientific (antigen selection) and 
clinical approach (patient population) a clinical development program would probably 
need 15 000–20 000 subjects. At the utmost it is considered to be realistic that an 
approval might be in order before the end of the decade.  But on the other hand the 
limited success rate in traditional therapies obviously has increased the interest level in 
vaccine therapies against S.aureus infections [66].  
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“Science is replacing ignorance with confusion” 
Nicolaus Copernicus 
 
 
 
 
 
 
 
  21
2  AIMS OF THE STUDY  
2.1 The hypothesis of the trials started in the early 1990 
Oral surgery usually leads to bacteraemia with a disparate microbiological flora were 
up to 1x102 different species were detectable using lysis filtration technique [29]. Very 
few of these species lead to infection or endocarditis and only in predisposed patients 
with valvular deformity or implanted heart valves. These few species especially, the 
Viridans streptococci or Staphylococci have characteristics and binding functions, 
giving them a clear advantage in the infectious process. These pathogens express 
surface bound proteins able to specifically mediate adherence to extracellular matrix 
protein [20, 77]. 
 
2.2 Specific Aims  
1. To increase knowledge about mechanisms in the infectious process and 
identification of the essential initial mechanisms and functions in the emergence 
and establishment of infection.  
2. To explore the feasibility of using purified surface bound proteins responsible 
for adhesion to different matrix proteins as vaccination components. 
3. To perform usable experimental adhesion models for in in vivo adhesion trials. 
4. To develop a wound infection model specially adapted for vaccination studies. 
The model should be simple, standardized and modified with only a small 
number of bacteria needed as inoculum to establish infection.  
5. To evaluate multicomponent immunization with different extra cellular proteins 
combined with surface bound proteins and to study the biological effects in vivo 
of antibodies targeting different steps in the infectious process.  
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3 MATERIAL AND METHODS  
3.1 Recombinant proteins 
The first recombinant protein (Gal-FnBP) used in paper I was previously performed in 
1987 [17] as described:  
The gene encoding FnBP (fibronectin binding protein) from Staphylococcus aureus 
strain 8325-4 expressed in chromosomal DNA was isolated from a gene bank in 
pBR322. The original clone containing a 6.5 Kb insert. The region of the fnbA-gene 
encoding the fibronectin-binding activity was identified and sub cloned in an 
expression vector based on the staphylococcal protein A gene, revealed in two gene 
products, 87 KD FnBA and 165 kD FnBB. The resulting product in E. coli is an 
extracellular fusion protein consisting of two IgG-binding domains of protein A 
followed by a fibronectin binding region. The fibronectin binding property is only a 3 x 
38 amino acid repeat located in the D-domain.  The gene is fused to the gene encoding 
Galactosidase and ligated into a plasmid inserted into E. coli. 
 
3.2 Protein purification 
E.coli HB101 with plasmids encoding, either three domains of Eap (henceforth called 
R13) or Efb-D (extracellular fibrinogen protein fused to the D-domain of the 
Fibronectin binding protein FnBP) as fusions to His6 tag, was grown in Luria broth at 
37 C. IPTG was added at OD600 =1.0 and cultivation was continued until harvest. 
Lysozyme was added and after centrifugation the supernatant was run through a Ni-
conjugated column and eluated with imidazole. The eluate was dialysed over night with 
PBS. The proteins were run on Phastgel and Western blot analysis and compared with 
LMW (low molecular weight standard proteins).  
  
3.3 Serum analyses 
Serum samples were taken from each animal including the control group after third 
immunization approximately one week after the last booster. Samples of blood was 
collected via the tail vein. The antibody titers were analysed by ELISA (Enzyme 
Linked Immuno Sorbent Assay). Microtiter wells (Costar) were coated over night with 
appropriate antigen. After rinsing with PBST (phosphate buffered saline with Tween) 
serum samples were added at serial dilutions and incubated at 1 h 37o. The antibodies 
were detected with HRP (hoarse radish peroxidase) - conjugated rabbit anti mouse or 
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rabbit anti rat monoclonal antibodies. OPD (Ortho-Phenylenediamine Dihydrochloride) 
tablets were used as substrate and stopped with H2SO4. The plates were then analysed 
in an ELISA reader at 492 nm. 
 
3.4 Adhesion trials in vitro   
Microtiter wells were coated over night with fibronectin, fibrinogen or collagen type II. 
Various amounts of S. aureus were added after pre-treatment with 50μl purified IgG 
from pooled immune serum or control, non-immune serum. The blocking effect were 
analysed in ELISA reader [78]. 
 
3.5 Experimental endocarditis model in rat.  
In this experimental method rats were catheterized with a venflon catheter via a. carotis 
communis on the right side. The catheter was then introduced on to the aortic valve and 
ligated for 24 hours. This resulted in a disturbed circulation in the environment 
surrounding the aortic valve, which resulted in deposition of fibrin thrombin complex 
directly on to the valve.  
 
The damaged heart valve is primary covered with fibrinogen, while also deeper layers 
of fibronectin in the tissue are superficially exposed. As no bacteria are present, these 
structures are named “sterile vegetation” NBTE (Non bacterial thrombotic 
endocarditis) (Fig.7). This is a condition that also occurs in the clinic, most often in 
patients having congenital valvular defects or malignant diseases [79-81]. Sterile 
vegetations are targets for circulating microorganisms with the ability to bind and 
adhere to fibrinogen and fibronectin in the vegetations. In this experimental 
endocarditis model the animals were intravenously infected with S. aureus via the tail 
vein. Circulating bacteria can thus colonize the valvular tissue and cause endocarditis. 
Bacterial adhesion can probably also be mediated by circulating fibrinogen, which 
binds to both the bacterium and the tissue. Pilot trials were also performed using this 
experimental endocarditis model were large inoculum 107 CFU (colony forming units) 
of S.aureus or S.mutans were compared with two non-pathogenic microorganisms, 
Bacillus subtilis and E coli, both lacking the ability to bind fibronectin and fibrinogen. 
The animals were analysed after 1 hour only to study the primary adhesion. This study 
showed that S. aureus and S. mutans adhered equally well to vegetation on the 
damaged aortic heart valve. However, these pathogens differed significantly in their 
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4  RESULTS AND DISCUSSION 
4.1 Immunization with fibronectin binding protein from Staphylococcus 
aureus protects against experimental endocarditis in rats (Paper I) 
 
4.1.1 Adhesion trials 
To study adhesion in vitro and in vivo we wanted to clarify the mechanisms behind 
bacterial adhesion. As the first step in the infection process the bacteria bind to various 
structures in the host organism, colonize and finally develop infection. On the cell 
surface of S. aureus adhesion proteins are expressed with specific affinity for matrix 
proteins such as fibronectin, fibrinogen, collagen, vitronectin and laminin. Binding 
fibronectin has been described to be the major virulence factor of S. aureus [64, 89]. 
The gene encoding the fibronectin binding protein was earlier cloned [17]. The 
fibronectin binding domain only 3 x 38 amino acid repeats called D-domain. The 3xD 
encoding DNA was fused with the gene encoding Galactosidase. The fused gene was 
inserted into a plasmid in E.coli, which allowed production in a large scale. The protein 
was purified and injected into Whistar rats together with Freud’s complete adjuvants. 
The fibronectin binding protein might be too small to be immunogenic by itself but 
when fused to a larger molecule  (Galactosidase) [90] the whole molecule is 
immunogenic (see materials an methods). Antibodies raised after immunization with 
Gal FnBp could be obtained in the serum targeting Galactosidase as well as the 
fibronectin-binding domain.  
 
Immune serum was then used for different trials in vitro concerning bacterial adherence 
to immobilized fibronectin. The immune sera with antibodies directed against the 
fibronectin binding protein on S.aureus whole bacterial cells proved to be able to block 
out the bacterial binding on to immobilized fibronectin in vitro (Fig.12).  
 
The trials showed that the immune response was committed via the adaptive immune 
system. A booster doze given after 12 months gave a quick response with high IgG 
antibody titers, indicating B-cell mediated immunological memory that sustained up to 
24 months. (Data not shown). 
 


  31
 
 
Fig.14. Number of bacteria on left hart valves with attached vegetations in vaccinated 
or non-vaccinated animals. Arrows indicate the mean log values. 
 
 
4.2 Reconsideration of the Role of Fibronectin Binding in Endocarditis 
Caused by Staphylococcus aureus (Paper II) 
 
The previous study showed that immunization with the fibronectin binding protein 
could protect against experimental endocarditis. The consensus during this time period 
was obvious that the fibronectin binding availability of S. aureus was the key to 
primary adhesion [64, 89]. Even today it is thought that fibronectin binding in the initial 
phase of an infection is of greatest importance [93]. To prove this theory we performed 
a similar study without immunizing.  Two isogenic strains were used. Wild type 8325-4 
and DU 5883, a double mutant strain with gene deletions in both of the fibronectin 
binding domains (see materials and methods). The gene substitution resulted in a 
double mutant strain FnBP A- FnBP B-. A DNA fragment encoding tetracycline 
resistance was inserted into fnbA and a fragment encoding erythromycin resistance was 
inserted into fnbB [85]. Adhesion trials were performed in vitro where the two isogenic 
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4.3 Streptococcus mutans major adhesion surface protein, P1 (I / II), 
does not contribute to attachment to valvular vegetation or to the 
development of endocarditis in a rat model (Paper III) 
 
In human endocarditis, the most common pathogen is the viridans streptococci, causing 
approximately 50 % of all the clinical cases [55, 96]. Oral viridians streptococci e.g. 
Streptococcus mitis and Streptococcus sanguis deemed to have caused 30-50% and 
Streptococcus aerginosus and Streptococcus mutans 8-18% of all viridans endocarditis 
cases. The Viridans Streptococci are mainly colonizing the oral cavity. After different 
types of oral surgery these pathogens can disseminate into the blood circulation and 
further on bind to sterile vegetations on the heart valvular tissue [97]. This is proposed 
to be the cause of the overrepresentation of Viridans streptococci in human 
endocarditis. S. mutans, usually associated with dental infections, e.g. dental caries, 
expresses a 185 kDa surface bound adhesion protein known as antigen P1 (I / II) [98]. 
This protein binds specifically to the enamel and dentin on the tooth surface. There may 
be a similarity between PI antigen that binds to the tooth surface with the 97 kDa sialo 
binding protein expressed in S. aureus [99]. The sialo binding protein indeed binds to 
dentin on the tooth surface too, but preferably to bone matrix structures causing 
osteomyelitis and septic arthritis. Sialo binding protein is a non-collagen binding 
protein and binds to crystalline structures in bone matrix, like uncovered dentin and 
sclerotic cartilage. In the clinical situation the tooth surface, a salivary pellicle 
consisting of a plurality of salivary and plasma proteins and also large amounts of 
fibrinogen and fibronectin cover both enamel and dentine. The pellicle is the main 
targets of the binding protein PI in Streptococcus mutans.  
 
The PI antigen is immunogenic, and low levels of antibodies are found in normal sera 
in man [100].  Increased antibody titer IgA and IgG to antigen P1 are found in patients 
with S. mutans endocarditis [101]. 
 
 Attempts has also been made to immunize against dental caries with PI/II, actually 
with limited success [102]. Whether this protein is causing adhesion of S.mutans on to 
injured heart valves was previously never investigated. The gene encoding the PI 
antigen has been cloned and sequenced [103].  A mutant of S. mutans (834) is lacking 
the gene (spaP) encoding the P1-surface antigen. The gene encoding Tetracyklin 
resistance were inserted into the spa P [104]. The fibronectin, fibrinogen and the 
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collagen binding capacity in the mutant strain (832) were compared with the isogenic 
wild type strain (NG8) in vitro. Both strains were unable to bind fibrinogen but they 
bound equally to collagen type II. Surprisingly the mutant strain bound twice as well to 
immobilized fibronectin compared to the wild type strain. This phenomenon was 
probably an effect of the gene insertion, which probably resulted in an overexpression 
of the fibronectin-binding domain. The binding was still weak in both strains and is 
most likely lacking clinical significance. Both strains were also compared and found to 
be equal in clearing out ratio after 1-hour intravenous infection.  
 
In the experimental rat endocarditis model the number of bacteria cultured from 
vegetations after 1 h adhesion trial and 48 h with manifest endocarditis were compared 
between the two strains. The results after growing vegetations clearly showed that no 
difference could be detected between the two strains. It appears that Pl antigen is 
irrelevant regarding primary adhesion and also as a virulence factor in endocarditis 
caused by S. mutans (Fig.16) [86]. 
 
 
 
 
 
 
Fig.16. Log number of bacteria recovered from aortic heart valve vegetations after 
infection with S. mutans strains NG8 and 834. Arrows indicate mean values. Symbols: 
closed circles strain NG8, open circles strain 834. 
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4.4 Collagen binding of Staphylococcus aureus is a virulence factor in 
experimental endocarditis (Paper IV) 
 
Based on the findings in paper II we concluded that the importance of the fibronectin 
binding capacity was a bit overestimated and many other factors were probably 
involved in the primary binding process. Further analyses of valvular tissues were 
performed. Vegetations caused by mechanical heart valve damage, intact valvular 
tissue from the right side and aortic endothelium were removed from catheterized 
animals, and non-catheterized animals respectively. The tissues were homogenized and 
analysed with Western-blot technique with conjugated specific antibodies. Collagens 
type II proved to exist in sterile vegetations (data not shown). Similar finding have also 
been described in earlier publications [105]. 
 
 In the present study two isogenic strains of S. aureus were used. A clinical strain, 
Phillips and a mutant strain P100 lacking the collagen binding capacity by a gene 
insertion of Gentamycin resistance [87]. Collagen adhesin-negative mutant PH100 was 
constructed by replacing the chromosomal collagen adhesin gene (cna) in a clinical 
strain, Phillips, with an inactivated copy of the gene (see materials and methods). 
 
The results after the in vitro adhesion studies between the two strains showed that the 
difference in collagen binding were obvious. The binding capacity on to stationary 
fibronectin and fibrionogen did not differ between the two strains.  
 
The two isogenic strains Phillips and PH100 were further on compared in vitro 
experiments in a rat model for catheter-induced infectious endocarditis. Separate 
groups of rats with traumatized aortic valve were infected intravenously with either of 
the two strains. After 1 hour of adhesion, we found no difference between the two 
strains (fig. 17). In rats sacrificed 24h after challenge the collagen binding strain was 
significantly more virulent compared to the mutant strain (p <0.001). The results were 
confirmed by further infection with a 1:1 mixture of the parent strain and the mutant as 
inoculum. In a mixed infection study the non-collagen binding strain were equal in 
adhesion after one-hour exposition. In 24h and 48h trials the wild type of S.aureus was 
superior to the mutant. This findings supported the theory that collagen binding is of 
limited importance concerning primary adhesion but of a grater importance in the next 
step, in other words in the establishment of infection (Fig.18 and 19) [106].  
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Fig.17. No of bacteria recovered from aortic (left) and pulmonary (right heart valves after 1 
hour. Horizontal lines indicate mean values. S.aureus Phillips (filled circles) and S.aureus PH 
100 (open circle). 
 
 
 
 
 
 
 
Fig.18. No of bacteria recovered from aortic (left) and Pulmonary (right) valves after 24 hours. 
Horizontal lines indicate mean values. Bottom line indicate  < 2 CFU recovered from each 
valve (detection limit). S.aureus Phillips () filled circle, S.aureus PH 100 () open circle. 
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Fig.19. Percentage of S.aureus strain Phillips recovered from aortic valves with 
vegetations at various times after animals were infected with a mix 1:1 of Phillips and 
PH 100. The total amount of recovered bacteria from each valve was estimated and 
compared with ratio in inoculate (X 2 test). P < ★ 0,01 and ★★ 0,10 vs. inoculum.  
 
To prove our theory the cna gene was also reintroduced into the collagen binding 
protein deficient mutant PH 100 on an autonomously replicating plasmid using a 
polymerase chain reaction amplified DNA fragment encompassing the cna gene. The 
resulting strain, called PHC, was tested in vitro in adherence trials on to stationary 
collagen, fibronectin and fibrinogen proving that collagen binding capacity was 
regained intermediate to that of Phillips and PH100.  PHC was also used in vivo in a 
mixed-inoculation experiment (PH100 and PHC).  The plasmids were lost at a high 
rate, probably because no antibiotic selection pressure could be applied in vivo, and 
therefore the results were inconclusive (data not shown). 
 
  
  38
4.5 Protective immunization against Staphylococcus aureus infection in 
a novel experimental wound model in mice (Paper V) 
Previous studies were mainly focused on primary bacterial adhesion blocking. The 
process in the establishment of an infection is obviously a bit more complicated. We 
wanted to create an infection model that could mimic the clinical situation as closely as 
possible, where damaged and avascular tissue is infected with a very small inoculum. 
The objective of further immune studies was to create a strong antibody response 
directed against mechanisms of S. aureus that interfere with the host's defence 
mechanisms. We particularly desired to produce an immunization method completely 
independent of resistance to antibiotics in the species. In addition to the previously 
mentioned adhesion proteins, S. aureus express extracellular proteins with ability to act 
and interfere in different stages during the infection process and also interfere with the 
host defence mechanisms e.g. Eap (extracellular adherence protein) and Efb, 
(extracellular fibrinogen binding protein). Efb has the ability to interfere, as well with 
the fibrin syntheses, as with complement activation (by binding to factor C3b).  
To assess the effect of multi-component immunization against Staphylococcus aureus 
infections a new experimental wound infection model in mice was developed. Before 
infection the animals were immunized with four recombinant S. aureus proteins 
expressed in Escherichia coli. 1: R 13 (domain 1-3 of extracellular adherence protein 
EAP), 2: Efb - D (a fusion protein containing extracellular fibrinogen binding protein 
(EFB) and the fibronectin binding D-domain of the fibronectin binding protein (FnBP) 
and 3: Clumping factor A (Clf A) which previously were proved to be important in the 
infectious process by binding fibrinogen [107].  
 
 Necrotic lesions were induced in mice by injecting venom from Bothrops Asper 
(Nicaragua) containing lysine-49 phospholipase A2 [108]. The toxin causes necrosis in 
humans and in the clinical situation the wounds habitually get secondarily infected with 
S.aureus. Further on the animals were infected with a low inoculum S.aureus strain 
Phillips (1x102 CFU). The wounds were swabbed and cultured day 3 and day 5, when 
the wounds were excised and analysed histologically.  
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a probable adaptive immune response. It is still unclear if the third mission of a vaccine 
is accomplished in this work. On the other hand, the blocking effect on diapedesis seen 
in Eap – ICAM 1 binding is presumably neutralized with antibodies directed to Eap 
(Paper V). This would in any case not prevent the recruitment of neutrofil cells into the 
infected environment. The combination of multicomponent vaccination used in Paper 
V might be one key to find alterative tratment strategies against multi drug resistant  
S.aureus infections. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“I do not like antibiotics. They kill bacteria!” 
Roland Möllby 
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5 CONCLUSIONS 
 
• The hypothesis in this thesis is based on two theories:  
1. Disturbed adhesion primarily affect the virulence of an invading 
microorganism. 
2. Immunization stimulate opsonization and make hidden virulence, and 
immunomodulation  factors visible to the immune system, and thus facilitate 
the ability to clear out infections. 
• Immunization with S. aureus adhesion proteins gave rise to specific antibodies, 
targeting binding proteins on the cell surface. A blocking effect in vitro was 
demonstrated. In experimental endocarditis model in vivo, a significant 
protection against infection after immunization was showed (Paper I). 
• A gene deletion in the fibronectin binding protein disabled S. aureus to bind 
immobilized fibronectin. Lacking fibronectin binding did not reduce virulence in 
experimental endocarditis in vivo (Paper II).  
• Endocarditis pathogen Streptococcus mutans lacking the PI (I/II) did not reduce 
bacterial binding or virulence in experimental endocarditis in vivo (Paper III). 
• S.aureus lacking the ability to bind collagen did not affect primary adhesion in 
experimental endocarditis model in vivo. However, it proved to be of 
considerable importance during the maintenance of an infection. (Paper IV). 
• Blocking antibodies against a single surface bound binding protein could 
eventually reduce the infectious load but bacteria adhered could as well later on 
establish infection. The significant reduced infection after immunization seen in 
paper I is probably not a blocking effect but rather a result of opsonization. 
• The experimental endocarditis model is a pure adhesion model. To study the 
infectious process more deeply, a sensitive wound model is more suitable to 
mimic the clinical situation.  
• Multicomponent immunization used in Paper V, gave rise to antibodies targeting 
different steps in the infectious process. A significant lower bacterial load and 
faster clearing out ratio was found in immunized group. The antigens used in 
Paper V could be one step in the right direction to find a working combination of 
effective vaccine components against infections caused by S. aureus. 
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6 FUTURE PERSPECTIVES 
 
Henceforth, we can expect that fused adhesion proteins could be used as immunization 
components against staphylococcal infections, passive or active immunization can be 
used as protective agents against establishment of infection and endocarditis in certain 
risk groups irrespectively of antibiotic resistance. To make a suitable vaccine against 
S.aureus it is important to find appropriate antigens, representative of most common 
pathogens. In Paper V all four antigens are expressed from the majority of S.aureus. All 
antigens recombinant produced are originally expressed and preserved in the 
chromosomal DNA in S.aureus, irrespective of antibiotic resistance. 
 
It is also interesting to find specific pathogens in different infections. What differs the 
pathogen in a burn injury after three days in hospital, from to the strain in the patients 
nose the moment before the accident? Knowledge of the specific pattern of a pathogen 
could ultimately lead to tailored immunization before e.g. an upcoming surgery or 
organ transplantation. 
Vaccination with recombinant proteins, alternatively, passive immunization with 
monoclonal antibody could inhibit the virulence and facilitating the elimination of 
invading microorganisms. The infectious model in mice used in Paper V was made 
sensitive with Bothrops asper snake venom and the infectious dose could be minimized 
to 0.5-1.0 x 102 bacteria. It is probably important to as closely as possible mimic the 
clinical situation.  In future trials we are planning to use a diabetes model in mice with 
a knock out gene encoding the leptin receptor. In this diabetes model spontaneous 
infections occur with Gram-positive bacteria. This model could represent an interesting 
challenge in vaccination trials.  
The use of Efb in clinical trials specifically directed against anticoagulation would be 
an exciting challenge and could be used to protect clotting and ischemic conditions. In 
Reconstructive Plastic Surgery, Efb could be used to extend the ischemic time in e.g. a 
free graft.  
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Eap is also an interesting protein with a variety of immunosuppressing properties.  Eap 
binding to ICAM-1cold be used in the clinical situation. Today there are two 
approaches to ICAM-1 therapy:  
1. Antibody-mediated neutralization of ICAM-1 or LFA-1 with an inhibition of 
cytotoxic CD8 T-cells in autoimmune conditions. 
2.  Pharmacological induction of ICAM-1 with recruiting cytotoxic CD8 T-cells in 
e.g. malignant conditions and infections. 
 One of these opposite treatments is administered depending on the type of disease. 
Studies using Eap to utilise the ICAM-1 blocking effect proves a similarity with 
monoclonal antibodies targeting ICAM-1[38] and could be used in the treatment of 
multiple sclerosis (MS), allergic asthma and also Rhinovirus infections. Also Eap 
binding the nuclear factor (NFκB) [37] with an inhibition of tube formation thus 
preventing angiogenesis is also an interesting perspective in the future as treatment of 
solid cancer and distant metastasis.  
S.aureus interference with the immune system might henceforth prove to influence 
other conditions, from chronic wounds to malignancies. It is interesting to understand 
why the extracellular protein Efb blocks out important steps in the complement system 
by its binding and inactivation of C3b. The MAC complex does not eradicate Gram-
positive capsular forming microorganisms like S.aureus. On the contrary, it is not 
unlikely that S.aureus paves the way for other pathogens to colonize wounds in 
different conditions e.g. diabetic foot ulcers. Further studies in this area are likely to 
open new opportunities for exciting research. 
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